Skip to main content
Fig. 3 | Cancer Communications

Fig. 3

From: Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial

Fig. 3

Forest plot illustrating the progression-free survival in prespecified subgroups. The arrows, above the scale, pointing to the right indicates that the upper limit of the 95% CI of HR exceeds 2. HR hazard ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance score

Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us